behind. The patients had no metastasis in the liver, peritoneum, or in distant organs at the time of surgery. No other previous or concomitant primary cancer was present. Patients had not received either chemotherapy or radiation therapy before surgery. All had experienced distal partial gastrectomy, proximal partial gastrectomy, or total gastrectomy with regional lymph node dissection to group 1 (D1), group 2 (D2), group 3 (D3), or group 4 (D4) by curative intent. None of the resection margins were positive for tumours. With regard to adjuvant chemotherapy, tegafur (FT-207, Taiho Co., Japan) (Palmeri et al, 1990) was used in 51 patients and uracil-tegafur (UFT, Taiho Co., Japan) (Maehara et al, 1990) in 40 patients; both were administered for 6 months to a year. Of the patients used in our study, 35 had no chemotherapy with FUs. These patients received either 600-800 mg FT twice, or 200-400 mg UFT two or three times daily orally. As a rule, the patients over 70 years old were not treated with anticancer agents in our hospital. Thus, the mean age was 57.4 in patients treated with FUs and 70.9 in patients not treated with FUs; there was a significant difference (P < 0.0001). However, there was no signficant difference in other clinicopathological factors (Table 1) . Mitomycin C (MMC) was used in 79 patients as follows: (i) 14 patientsintraperitoneal administration at a dose of 8-10 mg after surgical resection; (ii) 58 patients -intravenous administration at a dose of 8-30 mg after surgical resection and/or on the post-operative day; and (iii) 18 patients -continuous hyperthermic peritoneal perfusion (CHPP) with physiological saline that contained 10 µg ml -1 MMC (Hamazoe et al, 1994) . Moreover, cisplatin (CDDP) was used in 14 patients as follows: (i) six patients -intraperitoneal administration at a dose of 90-150 mg after surgical resection; (ii) eight patients -CHPP physiologic saline that contained 125-150 mg CDDP. Data concerning patients' outcomes, including overall survival and either presence or absence of metastases were available from all patients.
Immunohistochemistry
Thymidine phosphorylase expression Four-micrometre-thick sections were dewaxed in xylene, dehydrated in ethanol and then heated in a microwave oven (700 W) for 10 min to retrieve antigens. Endogenous peroxidase was blocked by incubation of samples in 3% hydrogen peroxide in methanol. After being washed with phosphate-buffered saline (PBS), they were incubated overnight with anti-dThdPase monoclonal antibody at a 1:500 dilution. This antibody was obtained from the Nippon Roche Research Center (Kanagawa, Japan). This antibody was prepared with an antigen consisting of human dThdPase purified from human colon cancer xenograft HCT116. The characterization of this antigen was reported by Nishida et al (1994) . Next, they were incubated with Envision + reagent (Dako Co. Ltd, Denmark) for 30 min at room temperature. Envision + reagent is peroxidase labelled polymer conjugated to goat anti-mouse immunoglobulins in Tris-HCl buffer containing carrier protein and an antimicrobial agent. The reaction products were visualized with diaminobenzidine as the chromogen and the sections were counterstained with methyl green. Normal mouse immunoglobulin G was used instead of the primary antibodies for negative controls. The degree of monoclonal antibody reactivity with individual tissue sections was considered positive if unequivocal staining of cytoplasm or nuclear compartment was seen in more than 5% of the tumour cells, as previously reported .
Microvessel detection and counting
A detection procedure for microvessels was performed using anti-CD34 monoclonal antibody (Nichirei Ltd, Tokyo, Japan). Envision + reagent was applied for immunoreaction. A single microvessel was defined as any brown immunostained endothelial cell separated from adjacent microvessels, tumour cells, and other connective tissue elements. The stained sections were screened at × 100 magnification (× 10 objective lens and × 10 ocular lens) under a light microscope (Vanox-S, Olympus, Tokyo, Japan) to identify the five regions of the section with the highest number of microvessels. The image was visualized on a computer display (Macintosh 7500/100, Apple Computer Inc., Cupertino, CA, USA) through a colour video camera module (XC-003, Sony, Tokyo, Japan) and colour image freezer (AE-6905C, Atto, Tokyo, Japan). Microvessels were counted in these areas at × 200 magnification (× 20 objective lens and × 10 ocular lens), and the average numbers of microvessels were recorded. The visualized area on the display was determined to be 0.075 mm 2 . Two observers (ST and HS) did the counting and the mean value was used for analysis. Large vessels with thick muscular walls were excluded in the counts. Observation of the lumen was not required for identification of a vessel.
Statistical analysis
The association of factors was evaluated by the χ 2 test. The significance of differences among means was determined by Student's t-test or Mann-Whitney U-test. Differences between survival curves were examined with the generalized Wilcoxon test. The influence of each variable on survival was assessed by the Cox proportional hazards model and a step-wise procedure. The accepted level of significance was P < 0.05. A Macintosh personal computer system (Stat View software; Abacus Concepts, Inc., Berkeley, CA, USA) was used for all statistical analyses.
RESULTS
Normal gastric mucosa was not immunoreactive with antidThdPase monoclonal antibody. TP was distributed in the cytoplasm or nuclear compartments of the carcinoma cells and infiltrating cells (Figure 1 ). The expression of TP was negative in 72, positive in 54. There was no correlation between the expression of TP and clinicopathological factors (Table 2) . the microvessel density was 49.0 ± 22.7 in TP-positive tumours and 41.5 ± 15.3 in TP-negative tumours. The expression of TP significantly correlated with microvessel density. The expression of TP significantly correlated with favourable prognosis in total cases (Figure 2 ). With regard to the treatment by FUs, there was no significant difference in prognosis between the patients treated by FUs and those not treated by FUs in total cases (data not shown). In patients with TP-positive tumours, however, the prognosis of patients given FUs was significantly better than that of those not given FUs (P < 0.05), whereas this difference was not observed in patients with TP-negative tumours (Figure 3 ). The expression of TP significantly correlated with favourable prognosis in patients treated by FUs, and with unfavourable prognosis in patients not treated by FUs (Figure 4) .
Multivariate analysis by Cox proportional hazards model and a step-wise procedure was performed to determine the significance of the treatment using FUs based on the status of the expression of TP. Covariates were: age, gender, tumour size, histology, depth of invasion, lymph node metastasis, lymphatic vessel invasion, blood vessel invasion, lymph node dissection, treatment by FUs, treatment by MMC, treatment by CDDP and treatment by CHPP. Treatment by FUs and lymph node metastasis were independent prognostic factors in the patients with TP-positive tumours using Cox proportional hazards model. Depth of invasion and lymphatic vessel invasion were independent prognostic factors in patients with TP-negative tumours (Table 3) . Moreover, multivariate analyses were performed based on the treatment by FUs. The expression of TP and lymph node metastasis were independent prognostic factors in the patients given FUs, and only lymph node metastasis was an independent prognostic factor in the patients not given FUs (Table 4) .
DISCUSSION
Solid tumours require neovascularization for growth and metastasis (Folkman, 1990) . It is also thought that the degree of tumour angiogenesis is related to clinical outcome; angiogenetic properties are believed to correlate with tumour aggressiveness (Bosari et al, 1992; Weidner et al, 1992; Gasparini et al, 1994; Maeda et al, 1995) . Many investigators have demonstrated that tumour cell secretion and activation of various endothelial growth factors, termed angiogenic factors, play crucial roles in the formation of the neovascularization (Kono et al, 1981; Zagzag et al, 1990; Toi et al, 1994 ). In the current study, we determined the correlation between the expression of TP and the microvessel density in advanced gastric carcinoma. The microvessel density in the TP-positive tumour was significantly higher than that in TPnegative tumour. This result is consistent with a previous report (Maeda et al, 1996) . The prognosis of patients with TP-positive tumours, however, was significantly better than that of patients with TP-negative tumours. Because high microvessel density correlates with poor prognosis in gastric carcinoma (Maeda et al, 1995) , as mentioned above, the present findings appear to be rather paradoxical. In fact, Maeda et al reported that the expression of TP correlated with unfavourable prognosis in patients with gastric carcinoma, including the early stage of the disease (Maeda et al, 1996) . Thus, we determined the correlation between the expression of TP and post-operative adjuvant chemotherapy using FUs, which were the most widely used chemotherapeutic agents for the treatment of gastric carcinoma in Japan. Both tegafur and uracil-tegafur are 5-FU prodrugs which can be given orally. Recently, it was reported that the expression of TP correlated with the efficacy of 5′-DFUR which was one of the 5-FU prodrugs because TP converted 5′-DFUR to 5-FU (Haraguchi et al, 1993; Ishikawa et al, 1998) . TP is also one of the enzymes that converted tegafur and uraciltegafur to 5-FU (Kono et al, 1981 (Kono et al, , 1983 . These findings imply that the expression of TP might correlate with the efficacy of chemotherapy using tegafur and uracil-tegafur.
There was no significant difference in prognosis between the patients treated by FUs and those not treated by FUs in total cases. In patients with TP-positive tumours, however, the prognosis of patients treated by FUs was significantly better than that of those not treated by FUs. Moreover, treatment by FUs and lymph node metastasis were independent prognostic factors in the patients with TP-positive tumours using Cox proportional hazards model. In addition, the expression of TP and lymph node metastasis were independent prognostic factors in the patients given FUs, although only lymph node metastasis was an independent prognostic factor in the patients not given FUs. These results indicated that the expression of TP in tumour cells might closely correlate with the efficacy of chemotherapy using FUs. The prognosis of the patients with TP-positive tumours was worse than that of those with TPnegative tumours who were not treated by FUs. Since a larger number of patients were treated by FUs, our results might be different from the results of previous studies. On the other hand, with regard to the efficacy of other adjuvant chemotherapy except FT and UFT (CDDP, MMC and CHPP), the prognosis of patients given MMC was significantly better than that of patients not given MMC (data not shown). However, there were no significant differences in prognosis in the treatment by CDDP and CHPP. Multivariate analysis indicated that these treatments were not independent prognostic factors in both status of the expression of TP.
Chemotherapy is not generally believed to be very effective for the eradication of massive tumours. However, it can be used to advantage against micrometastases invading the lymph node and/or lymph vessels and disseminated in the abdominal cavity after curative resection (Griswold et al, 1975; Schabel et al, 1976; Schabel et al, 1977) . Patients included in the current study had undergone curative gastrectomy. Thus, the correlation between the expression of TP and the efficacy of chemotherapy using FUs might be clear. The efficacy of chemotherapy is presumably dependent on the sensitivity of the tumour cells, which in turn is determined partially by the growth rate. Kubota et al (1995) reported that the overall survival rate of the chemo-sensitive group was significantly better than that of the chemo-resistant group according to the blind study in which their chemo-sensitivity was evaluated by histoculture drug response assay (HDRA). If patients with tumours sensitive to FUs can be identified before the initiation of therapy, FU-based treatment could be selected for this group. Such selection ability would spare patients unlikely to respond to the toxicity of anticancer agents and would allow faster progress in new drug development. It has been reported that the expression of thymidine synthetase (TS) correlated with sensitivity to FUs (Lenz et al, 1995; Leichman et al, 1997) . The determination of the expression of TP might also be useful for the purpose of treatment selection. The background of patients treated by FUs, however, was different from that of patients not treated by FUs in this retrospective study. Thus, it is necessary for our findings to be confirmed in randomized controlled studies.
In conclusion, we indicated the close relationship between the expression of TP and microvessel density or the efficacy of chemotherapy using FUs. Determination of the intra-tumoural expression of TP may enable clinicians to decide rationally whether FUs are appropriate first line chemotherapy on a patientby-patient basis. n 0 , no regional lymph node metastasis; n 1 , n 2 and n 3 , metastasis in groups 1, 2 and 3 lymph nodes respectively. c Lymphatic invasion: 1y0-1y3, grade of lymphatic vessel invasion. 0.0009 0.284 --a n 0 , no regional lymph node metastasis; n 1 , n 2 and n 3 , metastasis in groups 1, 2 and 3 lymph nodes respectively.
